ArticleMolecular neurobiology2026
Exploring the Expression Changes of Immune Genes in Alzheimer's Disease: A Study on ANXA1, VCAM1, and CCL2.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlzheimer's disease (AD) is a progressive neurological disorder associated with high prevalence. Numerous studies have been conducted to regulate the expression of inflammatory genes, indicating that any changes may ultimately lead the nervous system toward disease pathogenesis. ANXA1, VCAM1, and CCL2 are among the genes involved in immune and inflammatory pathways. In this study, we aim to examine their expression in individuals with Alzheimer's disease and healthy individuals using bioinformatics and laboratory methods. MATERIALS AND
methodsThis study aimed to analyze the differentially expressed genes (DEGs) in the entorhinal cortex with AD and identify featured genes related to AD. Gene expression profile GSE118553 was downloaded from Gene Expression Omnibus, including 37 AD and 24 control samples. Based on the filters applied to the data, the immune genes ANXA1, VCAM1, and CCL2 were selected to investigate changes in expression in Alzheimer's disease. The expression of ANXA1, VCAM1, and CCL2 genes in the peripheral blood of 50 AD patients and 50 healthy controls was examined using Real-time polymerase chain reaction (Real-time PCR). Subsequently, statistical analyses of expression differences and biomarker analysis were conducted on the resulting data.
findingsIn the peripheral blood of AD patients, ANXA1 expression increased, while VCAM1 expression decreased compared to controls. No significant change was observed in CCL2. the receiver operating characteristic (ROC) analysis showed that ANXA1 is effective in distinguishing AD from healthy individuals.
conclusionThis study provides new insights into the role of the ANXA1 gene in the pathogenesis of Alzheimer's disease, but further research is needed to confirm this role.
Indexed as
Identifiers
42142197What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.